In their application, the drugmakers cited follow-up data from a phase 3 clinical trial involving 2,228 children, which showed two doses of the vaccine were 100 percent effective against COVID-19. Thirty symptomatic COVID-19 cases occurred during the trial, but all were among the placebo group.
The FDA granted the vaccine emergency use authorization for children ages 12 to 15 in May and fully approved it for everyone 16 and up in August.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
